Abstract: The present invention is primarily directed to methods of genetic cluster analysis for use in determining the homogeneity and/or heterogeneity of a population or sub-population. Determination of the heterogeneity or homogeneity of a population sample is important in many areas including DNA fingerprinting in forensics and population-based studies such as clinical trials, case-control studies of risk factors, and gene mapping studies.

Abstract: The invention concerns the genomic sequence and cDNA sequences of the PG-3 gene. The invention also concerns biallelic markers of the PG-3 gene. The invention also concerns polypeptides encoded by the PG-3 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.

Abstract: The present invention relates to methods, software, and apparati for determining whether a genomic region harbors a gene associated with a detectable trait.

Abstract: The present invention is directed to a polynucleotide comprising open reading frames defining a coding region encoding a retinoblastoma binding protein (RBP-7) as well as regulatory regions located both at the 5? end and the 3? end of said coding region. The present invention also pertains to a polynucleotide carrying the natural regulation signals of the RBP-7 gene which is useful in order to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory region. The invention also concerns polypeptides encoded by the coding region of the RBP-7 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.

Abstract: The present invention relates to fluorescent probes which can be used in multicolor fluorescence in situ hybridization, and mainly chromosome painting. The probes intended for labeling a chromosome are such that they are composed of a set of DNA segments which are more represented in certain chromosome bands and which are obtained by IRS-PCR amplification from said chromosomes using PCR primers specific for the repeated and dispersed Alu and LINE DNA sequences. The invention comprises, in addition, methods of producing said probes, multicolor FISH methods which can use said probes as well as diagnostic kits comprising them. Finally, the invention comprises combinations of fluorophores and optical filters.

Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

Abstract: The sequences of 5? ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5? ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5? ESTs. The 5? ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5? ESTs. The 5? ESTs may also be used to design expression vectors and secretion vectors.

Abstract: The present invention is primarily directed to methods of genetic cluster analysis for use in determining the homogeneity and/or heterogeneity of a population or sub-population. Determination of the heterogeneity or homogeneity of a population sample is important in many areas including DNA fingerprinting in forensics and population-based studies such as clinical trials, case-control studies of risk factors, and gene mapping studies.

Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of PROLIXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

Abstract: The present invention relates to a purified or isolated polynucleotide encoding human CIDE B protein, the regulatory nucleic acids contained therein, polymorphic markers thereof, and the resulting encoded protein, as well as to methods and kits for detecting this polynucleotide and this protein. The present invention also pertains to a polynucleotide carrying the natural regulatory regions of the CIDE B gene which is useful, for example, to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory regions.

Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. Adipsin polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, insulin resistance, diabetes, and hypertension.

Abstract: The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.

Abstract: The invention concerns genomic and cDNA sequences of the human TBC-1 Gene. The invention also concerns polypeptides encoded by the TBC-1 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the TBC-1 gene useful in genetic analysis.

Abstract: The sequences of 5′ ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5′ ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5′ ESTs. The 5′ ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5′ ESTs. The 5′ ESTs may also be used to design expression vectors and secretion vectors.

Abstract: The invention relates to the use of PP2A/B&ggr; and to the use of a PP2A phosphatase comprising the PP2A/B&ggr; subunit for screening for modulators thereof. The use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators are further disclosed. The present invention further provides novel PP2A/B&ggr; subunits generated by alternative splicing events. The invention also discloses biallelic markers located in the gene encoding PP2A/B&ggr; and their use for diagnosing mental disorders.

Abstract: The invention provides polynucleotides and polypeptides encoding an isolated amyloid inhibitor protein (APIP) and compositions thereof. The polypeptides of the subject invention can be used to inhibit the catabolism or sequential cleavage of arnyloid beta precursor protein (APP) by Sequential cleavage of APP by beta secretase and gamma secretase.

Abstract: The invention provides polynucleotides including biallelic markers derived from genes involved in arachidonic acid metabolism and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

Abstract: The invention concerns CCRP-1 polynucleotides and polypeptides. The invention further relates to methods of directing polynucleotides, polypetides, and small molecules to mitochondria. The invention further relates to methods of reducing blood levels of fatty acids in an individual. The invention also concerns methods of identifying individuals who are at increased risk or who have a predisposition for developing, or present state of having, a diseases or disorder, such as obesity or heart disease, by determining the level of a CCRP-1 gene product in an individual.

Abstract: The sequences of 5′ ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5′ ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5′ ESTs. The 5′ ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5′ ESTs. The 5′ ESTs may also be used to design expression vectors and secretion vectors.